Clover Biopharmaceutical

View All

Clover gets fund; Libtayo for first-line Advanced NSCLC Subset
Clover biopharmaceuticals raises $230 M; BrainStorm after ALS; BARDA grants $5.65 M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset

Clover Biopharmaceuticals Raises $230 Million  Clover Biopharmaceuticals announced the completion of an oversubscribed $230 million Series C financing, summing total capital raised by the company during the last year over USD 400 million. The Series C round was co-led by GL Ventures and Temasek, with partic...

Find More

Coronavirus
Wuhan Coronavirus: A global emergency

An outbreak of a mysterious viral infection, 2019-nCoV – coronavirus, has set the whole world on toes, claiming the lives of more than 800 people in China, surpassing the death toll caused from SARS, reports the Chinese government.  An infection with the symptoms more or less like pneumonia, known by the name ...

Find More